The 2021 edition of the National Medical Insurance Catalog will reduce the average price of 67 new drugs by more than 60% through negotiation, covering the needs for drugs such as tumors, chronic diseases, and rare diseases.

To reduce the burden of drug costs for the masses, not only is the drug "reimbursable" in medical insurance, but also allows the masses to use good drugs conveniently and quickly, and improves the availability of negotiated drugs.

To this end, the National Medical Insurance Administration proposed a "dual-channel" drug purchase mechanism. As of the end of January this year, the negotiated drugs in the new version of the National Medical Insurance Drug Catalog during the agreement period were available in 154,700 designated medical institutions across the country.

　　Xie Junbo, a citizen of Huzhou, Zhejiang Province, purchased a drug for the National Medical Insurance Negotiation at a retail pharmacy, which is a targeted drug for the treatment of ovarian cancer.

　　Xie Junbo, a resident of Huzhou: I used to get medicine in the outpatient pharmacy of the hospital after the doctor checked it out. Now, after the doctor checked it out, I asked the doctor to give me a prescription, and I just came here to dispense it.

We paid attention to (this medicine) from the beginning. At that time, it was about 25,000 yuan (a box). At the end of 2020, a national (drug) negotiation was held, and then it was directly reduced to 6,000 yuan (a box). At the end of last year, the state negotiated again, from 6,000 yuan to 4,500 yuan. The reimbursement ratio of pharmacies is exactly the same as that of hospitals.

　　In order to solve the problem of negotiating drug delivery, in May last year, the National Medical Insurance Bureau proposed a “dual-channel” management mechanism for negotiated drugs, which for the first time included designated retail pharmacies in the supply guarantee scope of medical insurance drugs at the national level, and implemented a unified payment policy with medical institutions. .

　　Hu Xiaobo, Deputy Director of the Medical Insurance Management Service Center of Huzhou City, Zhejiang Province: There are 275 kinds of negotiating drugs, mainly involving chronic diseases such as hypertension and diabetes, and anti-tumor drugs. The average decrease of the newly included negotiating drugs is more than 60%, which greatly reduces the cost of the common people. cost burden.

　　As of the end of January 2022, the negotiated drugs in the new version of the National Medical Insurance Drug Catalog during the agreement period will be available in 154,700 designated medical institutions across the country, including 42,100 designated medical institutions and 112,600 designated retail pharmacies, respectively.

"Dual-channel" retail pharmacies and designated medical institutions complement each other to better facilitate patients and meet the medication needs of insured persons.

　　Zhong Jingmei, manager of a large pharmacy: Since the implementation of the "dual channel", the monthly service volume of our pharmacy is three times that of the previous one. It is also convenient for ordinary people to buy medicines and their satisfaction has been greatly improved.

　　Data from the National Medical Insurance Bureau shows that in January this year alone, 17.7387 million drug reimbursements were negotiated during the agreement period, and the medical insurance fund expenditure was 5.197 billion yuan, with an average actual reimbursement ratio of 69.12%.